Drew Moghanaki: Evaluating the first 100 participants treated with lung SBRT through 2022 of the VALOR study

Drew Moghanaki shared a post on X about a recent paper by Timothy Ritter et al. published in Elsevier.

“Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR)”

Authors: Timothy Ritter, Robert Timmerman, Hena Hanfi, Jatinder Palta, Drew Moghanaki et al.

“The VALOR study team publishes its’ observations evaluating the first 100 participants treated with lung SBRT through 2022. The planning guide is included in the appendix. Today, nearly 400 of 670 are randomized.”

Source: Drew Moghanaki/X

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).